<div id="readability-page-1"><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Eli Lilly and Company, Pfizer,  and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and related therapies. For investors, they offer exposure to potential high growth from successful drug pipelines and approvals, but also carry distinctive risks—regulatory decisions, clinical-trial outcomes, patent expirations, and large R&amp;D costs—that can make them volatile. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><ul><li>The Top 3 Investment Themes That Will Dominate 2026</li></ul><p>Read Our Latest Research Report on PFE</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>Further Reading</h2><ul><li>MarketBeat's Top Five Stocks to Own in December 2025</li><li>Financial Sector Breaks Out as Capital Rotates and Leadership Shifts</li><li>Super Micro's Sell-Off Is a Mirage—Here’s Why the Rally May Come Back Fast</li><li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li><li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li><li>3 Underrated Robotics Stocks Poised for Huge Gains</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>MarketBeat's stock screener tool identifies Eli Lilly, Pfizer, and AbbVie as promising pharmaceutical stocks to watch. These companies offer potential high growth from successful drug pipelines but carry risks like regulatory decisions and clinical-trial outcomes. Eli Lilly has a Moderate Buy rating, but top analysts suggest other stocks may be better buys. Pfizer is investing in weight loss drugs, and AbbVie offers treatments for various diseases.</p>

- Pfizer, Eli Lilly, and AbbVie are highlighted as key pharmaceutical stocks to monitor due to their significant trading volumes.  
- These companies are involved in the research and development of various drugs, including treatments for diabetes and obesity, and face risks such as regulatory decisions and clinical trial outcomes.  
- The article emphasizes the potential for high growth in pharmaceutical stocks while also noting the inherent volatility associated with the industry.

Promising Pharmaceutical Stocks To Watch Now - December 15th